Contemporary Updates and Expert Insights in Hypoparathyroidism

Contemporary Updates and Expert Insights in Hypoparathyroidism

Step 1: Self-Assessment Survey Step 1: Self-Assessment Survey
The survey is designed to help clinicians evaluate their knowledge, competence, and practice patterns related to the care of patients with hypoparathyroidism.

Step 1: Self-Assessment Survey Step 2: E-Publication (details below)

Maximum Credits:




Maximum Credits:


Maximum Credits:

Additional patient and healthcare provider resources are available here.

The self assessment survey is not CME certified and, therefore, does not offer any CME/CE credit.

Overview: This online, audio-enhanced, CME-certified publication, sponsored by Med-IQ, discusses the current practices for diagnosing and managing patients with hypoparathyroidism, including the potential role of parathyroid hormone agents currently in clinical development. Designed for endocrinologists, this publication also features audio clips of expert perspectives from John P. Bilezikian, MD, and Bart L. Clarke, MD, on practical issues regarding state-of-the-art patient care.

CME Information:

This activity was developed through a collaboration between the Endocrine Society and Med-IQ.

The Endocrine Society

Learning Objectives
Upon completion, participants should be able to:

  • Discuss the pathophysiology of hypoparathyroidism
  • Design management strategies to minimize the clinical challenges experienced by patients with hypoparathyroidism and improve their quality of life
  • Evaluate patients with signs and symptoms of hypoparathyroidism using appropriate laboratory tests
  • Develop evidence-based strategies to manage the clinical manifestation of hypoparathyroidism and achieve treatment goals

John P. Bilezikian, MD
Professor of Medicine
Chief, Division of Endocrinology
Director, Metabolic Bone Diseases Program
Columbia University
College of Physicians and Surgeons
Division of Endocrinology
New York, NY

Bart L. Clarke, MD
Professor of Medicine
College of Medicine, Mayo Clinic
Consultant and Chair, Metabolic Bone Disease Core Group
Mayo Clinic Division of Endocrinology, Diabetes, Metabolism and Nutrition
Rochester, MN

Activity Planners
JaNeen Dancy, PharmD
Clinical Content Manager
Baltimore, MD

Iwona Misiuta, PhD, MHA
Clinical Content Manager
Baltimore, MD

Rebecca L. Julian, MS, ELS
Senior Managing Editor
Baltimore, MD

Amy Sison
Director of Continuing Medical Education
Baltimore, MD

Katherine Kahn
Southampton, MA

Target Audience
This activity is intended for endocrinologists.

Series Overview/Statement of Need
Although a rare endocrine disorder, hypoparathyroidism (HPT) can have significant, but sometimes underappreciated, effects on quality of life (QOL). In some cases, HPT can be profoundly debilitating, causing severe muscle cramping and pain, but many patients may live relatively normal lives with pharmacologic management. Clinicians managing patients with HPT face a number of obstacles. Diagnosing HPT can be difficult, causes are varied, and symptoms may not be obvious. The long-term management of calcium balance is particularly challenging, but critical because severe hypocalcemia can be life-threatening. Clinicians who treat patients with this disorder must be well educated on recent advances in the diagnosis and treatment of HPT and must also be aware of effective strategies to improve the overall well-being and QOL of their patients throughout the course of this chronic disease.

Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Method of Participation
The estimated time to complete this activity, including review of material, is 1 hour. This CME activity consists of a 1.0-credit online publication. To receive credit, participants must read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, achieving a minimum score of 70%. If learners do not achieve a passing score of 70%, they have the option to retake the post-test.

Original Release Date: September 13, 2013
Recertification Date: March 2, 2015
Expiration Date: March 1, 2016

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society, Med-IQ, and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society and Med-IQ have reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationship(s), which has/have been resolved through an established COI resolution process, and have stated that this/these reported relationship(s) will not have any impact on their ability to give an unbiased presentation. 

The following faculty reported relevant financial relationships:
John Bilezikian, MD: Consultant, Amgen, Merck & Co., Inc., Radius Health, Inc.; Contracted Research, NPS Pharmaceuticals, Inc.; Royalties, Elsevier

Bart Clarke, MD: Consultant, Amgen; Contracted Research, NPS Pharmaceuticals, Inc.

The following medical writer who planned and/or reviewed content for this activity reported no relevant financial relationships: Katherine Kahn

The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships: E. Michael Lewiecki, MD: Consultant & Research Grant Support, Amgen, Eli Lilly and Company, Merck & Co., Inc.; Consultant, AgNovos Healthcare, Radius Health, Inc., TheraNova

The following Med-IQ staff who planned and/or reviewed content for this activity reported no relevant financial relationships: Jaclyn Zendrian, JaNeen Dancy, PharmD, Iwona Misiuta, PhD, MHA, Rebecca L. Julian, MS, Amy Sison

The Endocrine Society and Med-IQ staff associated with the development of content for this activity reported no relevant financial relationships.

Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Special Programs Committee of the Endocrine Society. The commercial supporters of this activity have no influence over the planning of this CME activity.

Policy On Unlabeled/Off-Label Use
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

ADA Statement
The Endocrine Society and Med-IQ fully comply with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

Hardware/Software Requirements
Operating System
Microsoft Windows® 2000, XP, Vista
Mac OS 10.1 or later

Microsoft Internet Explorer 6.0 or later

Mozilla Firefox 5.0 or later

Google Chrome

Apple Safari

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader

Adobe Flash Player
Adobe Flash Player 9 or later

Connection Type
High bandwidth (300k) is strongly recommended
Low bandwidth (100k) results in less than optimal quality
Dial-up/modem is not recommended

For technical support, go to

Contact Information
For questions about obtaining CME credit, please contact the Endocrine Society at

For questions or comments about the content of this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or e-mail

Privacy & Confidentiality Statement
The Endocrine Society and Med-IQ will record learner's personal information as provided on evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from NPS Pharmaceuticals, Inc.

© 2014 Endocrine Society. All rights reserved.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email For technical assistance, please refer to our support manual.

Our website uses cookies to improve your experience. To learn more about the cookies we use, please visit our Privacy Notice and Terms of Use.